CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.

MLA

Bexte, Tobias, et al. “CRISPR-Cas9 Based Gene Editing of the Immune Checkpoint NKG2A Enhances NK Cell Mediated Cytotoxicity against Multiple Myeloma.” OncoImmunology, vol. 11, no. 1, Jan. 2022, pp. 1–6. EBSCOhost, https://doi.org/10.1080/2162402X.2022.2081415.

APA

Bexte, T., Alzubi, J., Reindl, L. M., Wendel, P., Schubert, R., Salzmann-Manrique, E., von Metzler, I., Cathomen, T., & Ullrich, E. (2022). CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma. OncoImmunology, 11(1), 1–6. https://doi.org/10.1080/2162402X.2022.2081415

Chicago

Bexte, Tobias, Jamal Alzubi, Lisa Marie Reindl, Philipp Wendel, Ralf Schubert, Emilia Salzmann-Manrique, Ivana von Metzler, Toni Cathomen, and Evelyn Ullrich. 2022. “CRISPR-Cas9 Based Gene Editing of the Immune Checkpoint NKG2A Enhances NK Cell Mediated Cytotoxicity against Multiple Myeloma.” OncoImmunology 11 (1): 1–6. doi:10.1080/2162402X.2022.2081415.